Scancell Holdings PLC

SCLP

Company Profile

  • Business description

    Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.

  • Contact

    Sanders Road
    Unit 202, Bellhouse Building
    Oxford Science Park
    OxfordOX4 4GD
    GBR

    T: +44 1865582066

    https://www.scancell.co.uk

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 April 2026

    Employees

    61

Stocks News & Analysis

stocks

Microsoft earnings: Strong, including Azure, but overall guidance is in line

We think Microsoft stock is moderately undervalued.
stocks

After earnings, is Tesla stock a buy, a sell, or fairly valued?

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
stocks

3 cheap fully franked stocks

Well priced Aussie shares that offer a tax rebate.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,178.0028.70-0.31%
CAC 408,113.4743.82-0.54%
DAX 4023,944.08174.81-0.72%
Dow JONES (US)47,595.6273.500.15%
FTSE 1009,717.8042.26-0.43%
HKSE25,906.65376.04-1.43%
NASDAQ23,793.46212.310.90%
Nikkei 22552,411.341,085.732.12%
NZX 50 Index13,548.3289.030.66%
S&P 5006,854.5332.190.47%
S&P/ASX 2008,881.9031.30-0.35%
SSE Composite Index3,954.7932.11-0.81%

Market Movers